Get notified when HALO files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Hypercon Partner May Return Target By September 2026 (new) — Could trigger material impairment charge to intangibles and goodwill from Elektrofi acquisition if partner returns target without nominating alternative with similar cash flows.
  • Janssen Darzalex Patent Revocations In Europe (new) — European Patent Office revoked two Janssen co-formulation patents for DARZALEX SC in March 2023 and October 2024; permanent loss of patent rights if not overturned on appeal.
  • Federal Workforce Cuts And Tariffs (new) — Workforce reductions at FDA could delay product approvals; new tariff policies could increase costs, disrupt supply chains, and create market volatility in biopharmaceutical sector.
  • Merck Patent Infringement Lawsuit (new) — Halozyme filed lawsuit in April 2025 alleging Merck is using MDASE technology for subcutaneous Keytruda without authorization; litigation costly, lengthy, and uncertain in outcome.
NASDAQ: HALO HALOZYME THERAPEUTICS, INC. 10-Q

Q1 revenue +34% YoY; $1B buyback authorized; Hypercon partner may return target by Sept

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

  • high

    Royalty revenue grew 43% YoY to $240.7M; net income rose 27% to $150.0M. Three new ENHANZE partners added (Merus, Skye Bioscience, GSK), with GSK collaboration marking first antibody-drug conjugate application.

    MD&A: Revenue & Partnerships verify on EDGAR →
  • high

    Hypercon partner evaluating potential target return by September 2026; if returned without alternative target, could trigger material impairment charge to intangibles and goodwill from Elektrofi acquisition.

    MD&A: Hypercon Risk verify on EDGAR →
  • high

    Issued $1.5B in new convertible notes (2031/2032) and used proceeds to repurchase $1.02B of 2027/2028 notes at premium, extending maturities and reducing near-term obligations. $208.7M of 2027 notes now current.

    Notes: Debt Refinancing view on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (UNF 10-Q) is open in full — no account needed.

Partner

Trade HALO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jul 9, 2026 · How we verify